Alprazolam: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
Terminology: medicine → med (shorter form per user preference) |
MDElliottMD (talk | contribs) Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name) |
||
| Line 16: | Line 16: | ||
| intro = '''Alprazolam''' is a high-potency, intermediate-acting triazolobenzodiazepine, FDA-approved for generalized anxiety disorder, panic disorder, and anxiety associated with depression. Its rapid onset, short-to-intermediate half-life, and high potency make it both clinically effective and uniquely problematic among benzodiazepines: alprazolam has consistently been associated with the highest rates of dependence, misuse, and difficult withdrawal in its class. For most chronic anxiety treatment, longer-acting agents (clonazepam, diazepam) or non-benzodiazepine alternatives (SSRIs, SNRIs, buspirone) are preferred. | | intro = '''Alprazolam''' is a high-potency, intermediate-acting triazolobenzodiazepine, FDA-approved for generalized anxiety disorder, panic disorder, and anxiety associated with depression. Its rapid onset, short-to-intermediate half-life, and high potency make it both clinically effective and uniquely problematic among benzodiazepines: alprazolam has consistently been associated with the highest rates of dependence, misuse, and difficult withdrawal in its class. For most chronic anxiety treatment, longer-acting agents (clonazepam, diazepam) or non-benzodiazepine alternatives (SSRIs, SNRIs, buspirone) are preferred. | ||
| pharmacokinetics = Rapid and near-complete oral absorption; bioavailability ~80–100%. Peak plasma levels in 1–2 hours (IR) or ~9 hours (XR). Highly protein-bound (~80%). Metabolized hepatically by '''CYP3A4''' to α-hydroxyalprazolam and 4-hydroxyalprazolam — both pharmacologically active but present at low concentrations. Half-life ~11 hours in healthy adults; substantially prolonged in elderly patients, obesity, and hepatic impairment. The relatively short half-life relative to diazepam contributes to inter-dose rebound anxiety with TID dosing and to the severity of its discontinuation syndrome. | | pharmacokinetics = Rapid and near-complete oral absorption; bioavailability ~80–100%. Peak plasma levels in 1–2 hours (IR) or ~9 hours (XR). Highly protein-bound (~80%). Metabolized hepatically by '''CYP3A4''' to α-hydroxyalprazolam and 4-hydroxyalprazolam — both pharmacologically active but present at low concentrations. Half-life ~11 hours in healthy adults; substantially prolonged in elderly patients, obesity, and hepatic impairment. The relatively short half-life relative to diazepam contributes to inter-dose rebound anxiety with TID dosing and to the severity of its discontinuation syndrome. | ||
| pharmacodynamics = Binds to the benzodiazepine site on GABA<sub>A</sub> receptors, allosterically enhancing GABA-induced chloride channel opening (increased '''frequency''' of opening, not duration — distinguishing benzodiazepines from barbiturates). This hyperpolarizes the neuron, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal muscle relaxant effects. Compared to other benzodiazepines, alprazolam shows relatively greater anxiolytic and antipanic effect with somewhat less sedation per unit anxiolysis, attributed in part to its triazole ring. Some evidence of mild antidepressant activity at higher doses, the basis for its "anxiety with depression" | | pharmacodynamics = Binds to the benzodiazepine site on GABA<sub>A</sub> receptors, allosterically enhancing GABA-induced chloride channel opening (increased '''frequency''' of opening, not duration — distinguishing benzodiazepines from barbiturates). This hyperpolarizes the neuron, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal muscle relaxant effects. Compared to other benzodiazepines, alprazolam shows relatively greater anxiolytic and antipanic effect with somewhat less sedation per unit anxiolysis, attributed in part to its triazole ring. Some evidence of mild antidepressant activity at higher doses, the basis for its "anxiety with depression" problem. | ||
| indications = * Generalized anxiety disorder | | indications = * Generalized anxiety disorder | ||
* Panic disorder (with or without agoraphobia) | * Panic disorder (with or without agoraphobia) | ||